Amgen's Repatha lowers LDL-C in Phase III for dyslipidemia in Type II diabetics

Amgen Inc. (NASDAQ:AMGN) reported in June that Repatha evolocumab met the co-primary endpoints in the Phase III BANTING trial to treat hypercholesterolemia or mixed dyslipidemia in Type II diabetics taking the maximum tolerated dose of moderate/high-intensity statin therapy. Repatha significantly reduced mean LDL-C from baseline to week 12 by 53.1% and from baseline to the mean of weeks 10 and 12 by 64.1% vs. placebo (p<0.0001 for both). Data were presented at the American Diabetes Association meeting in Orlando.

The double-blind, international trial enrolled 421 patients to receive placebo or once-monthly 420 mg subcutaneous Repatha for 12 weeks added to optimized background statin therapy...